Minerva Neurosciences to Host R&D Day Focused on Unmet Needs and Emerging Treatment Strategies in Schizophrenia

WALTHAM, Mass., Feb. 21, 2017 (GLOBE NEWSWIRE) – Minerva Neurosciences, Inc. (Nasdaq:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, will host a Research and Development Day to highlight unmet needs, including negative symptoms and cognitive impairment, and emerging treatment strategies in schizophrenia in New York City on March 2, 2017 from 8:00 am to 9:30 am Eastern Time.

The meeting will feature presentations by key opinion leaders Philip Harvey, PhD (University of Miami) and René Kahn, MD, PhD (Mount Sinai), who will discuss the current treatment landscape for schizophrenia. Dr. Remy Luthringer, president and chief executive officer of Minerva, will provide an overview of the Company’s ongoing clinical development work with MIN-101, including the Company’s clinical strategy moving forward. The presenters will be available to answer questions following the breakfast.

A live and archived webcast of the event, with slides, will be available at http://lifesci.rampard.com/20170302/reg.jsp and on the Investors section of the Company’s website at http://ir.minervaneurosciences.com.

More: http://www.pharmiweb.com/pressreleases/pressrel.asp?ROW_ID=206463#.WKxeFfKhHIU#ixzz4ZKoXTQzN


Haha! I actually beat you to it today!